Drug Type Monoclonal antibody |
Synonyms STSA 1002, STSA-1002 |
Target |
Mechanism C5a inhibitors(complement C5a inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Distress Syndrome, Adult | Phase 2 | CN | 09 Dec 2023 | |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 1 | US | 31 Jan 2023 | |
COVID-19 | Phase 1 | US | 22 Aug 2022 | |
COVID-19 | Phase 1 | CN | 22 Aug 2022 |